Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia

Franklin C. Lowe, John D. McConnell, Perry B. Hudson, Nicholas A. Romas, Rex Boake, Michael Lieber, Mostafa Elhilali, Jack Geller, Juliane Imperto-McGinely, Gerald L. Andriole, Reginald C. Bruskewitz, Patrick C. Walsh, Georg Bartsch, John N. Nacey, Sukrut Shah, Frances Pappas, Amy Ko, Thomas Cook, Elizabeth Stoner, Joanne Waldstreicher

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Objectives. To summarize the 6-year clinical trial data with finasteride. Benign prostatic hyperplasia is a chronic and progressive disease and therefore assessment of long-term safety and efficacy is important. Methods. The North American and International Phase III Finasteride trials enrolled symptomatic men with enlarged prostate glands. The initial 1-year placebo-controlled study was followed by a 5-year open-label extension. In total, 6-year finasteride data were available in 487 patients originally randomized to finasteride, and 5-year data were available on 238 patients originally randomized to placebo. Results. After 6 years of treatment with finasteride 5 mg, the mean quasi-American Urological Association Symptom Score improved by 4.0 points, the median prostate volume decreased by 24%, and the mean maximal urinary flow rate increased by 2.9 mL/s (P

Original languageEnglish (US)
Pages (from-to)791-796
Number of pages6
JournalUrology
Volume61
Issue number4
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Finasteride
Prostatic Hyperplasia
Prostate
Placebos
Chronic Disease
Clinical Trials
Safety

ASJC Scopus subject areas

  • Urology

Cite this

Lowe, F. C., McConnell, J. D., Hudson, P. B., Romas, N. A., Boake, R., Lieber, M., ... Waldstreicher, J. (2003). Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology, 61(4), 791-796. https://doi.org/10.1016/S0090-4295(02)02548-7

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. / Lowe, Franklin C.; McConnell, John D.; Hudson, Perry B.; Romas, Nicholas A.; Boake, Rex; Lieber, Michael; Elhilali, Mostafa; Geller, Jack; Imperto-McGinely, Juliane; Andriole, Gerald L.; Bruskewitz, Reginald C.; Walsh, Patrick C.; Bartsch, Georg; Nacey, John N.; Shah, Sukrut; Pappas, Frances; Ko, Amy; Cook, Thomas; Stoner, Elizabeth; Waldstreicher, Joanne.

In: Urology, Vol. 61, No. 4, 01.04.2003, p. 791-796.

Research output: Contribution to journalArticle

Lowe, FC, McConnell, JD, Hudson, PB, Romas, NA, Boake, R, Lieber, M, Elhilali, M, Geller, J, Imperto-McGinely, J, Andriole, GL, Bruskewitz, RC, Walsh, PC, Bartsch, G, Nacey, JN, Shah, S, Pappas, F, Ko, A, Cook, T, Stoner, E & Waldstreicher, J 2003, 'Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia', Urology, vol. 61, no. 4, pp. 791-796. https://doi.org/10.1016/S0090-4295(02)02548-7
Lowe, Franklin C. ; McConnell, John D. ; Hudson, Perry B. ; Romas, Nicholas A. ; Boake, Rex ; Lieber, Michael ; Elhilali, Mostafa ; Geller, Jack ; Imperto-McGinely, Juliane ; Andriole, Gerald L. ; Bruskewitz, Reginald C. ; Walsh, Patrick C. ; Bartsch, Georg ; Nacey, John N. ; Shah, Sukrut ; Pappas, Frances ; Ko, Amy ; Cook, Thomas ; Stoner, Elizabeth ; Waldstreicher, Joanne. / Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. In: Urology. 2003 ; Vol. 61, No. 4. pp. 791-796.
@article{01afff194a2549ae9f01de2d0fe46dc0,
title = "Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia",
abstract = "Objectives. To summarize the 6-year clinical trial data with finasteride. Benign prostatic hyperplasia is a chronic and progressive disease and therefore assessment of long-term safety and efficacy is important. Methods. The North American and International Phase III Finasteride trials enrolled symptomatic men with enlarged prostate glands. The initial 1-year placebo-controlled study was followed by a 5-year open-label extension. In total, 6-year finasteride data were available in 487 patients originally randomized to finasteride, and 5-year data were available on 238 patients originally randomized to placebo. Results. After 6 years of treatment with finasteride 5 mg, the mean quasi-American Urological Association Symptom Score improved by 4.0 points, the median prostate volume decreased by 24{\%}, and the mean maximal urinary flow rate increased by 2.9 mL/s (P",
author = "Lowe, {Franklin C.} and McConnell, {John D.} and Hudson, {Perry B.} and Romas, {Nicholas A.} and Rex Boake and Michael Lieber and Mostafa Elhilali and Jack Geller and Juliane Imperto-McGinely and Andriole, {Gerald L.} and Bruskewitz, {Reginald C.} and Walsh, {Patrick C.} and Georg Bartsch and Nacey, {John N.} and Sukrut Shah and Frances Pappas and Amy Ko and Thomas Cook and Elizabeth Stoner and Joanne Waldstreicher",
year = "2003",
month = "4",
day = "1",
doi = "10.1016/S0090-4295(02)02548-7",
language = "English (US)",
volume = "61",
pages = "791--796",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia

AU - Lowe, Franklin C.

AU - McConnell, John D.

AU - Hudson, Perry B.

AU - Romas, Nicholas A.

AU - Boake, Rex

AU - Lieber, Michael

AU - Elhilali, Mostafa

AU - Geller, Jack

AU - Imperto-McGinely, Juliane

AU - Andriole, Gerald L.

AU - Bruskewitz, Reginald C.

AU - Walsh, Patrick C.

AU - Bartsch, Georg

AU - Nacey, John N.

AU - Shah, Sukrut

AU - Pappas, Frances

AU - Ko, Amy

AU - Cook, Thomas

AU - Stoner, Elizabeth

AU - Waldstreicher, Joanne

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Objectives. To summarize the 6-year clinical trial data with finasteride. Benign prostatic hyperplasia is a chronic and progressive disease and therefore assessment of long-term safety and efficacy is important. Methods. The North American and International Phase III Finasteride trials enrolled symptomatic men with enlarged prostate glands. The initial 1-year placebo-controlled study was followed by a 5-year open-label extension. In total, 6-year finasteride data were available in 487 patients originally randomized to finasteride, and 5-year data were available on 238 patients originally randomized to placebo. Results. After 6 years of treatment with finasteride 5 mg, the mean quasi-American Urological Association Symptom Score improved by 4.0 points, the median prostate volume decreased by 24%, and the mean maximal urinary flow rate increased by 2.9 mL/s (P

AB - Objectives. To summarize the 6-year clinical trial data with finasteride. Benign prostatic hyperplasia is a chronic and progressive disease and therefore assessment of long-term safety and efficacy is important. Methods. The North American and International Phase III Finasteride trials enrolled symptomatic men with enlarged prostate glands. The initial 1-year placebo-controlled study was followed by a 5-year open-label extension. In total, 6-year finasteride data were available in 487 patients originally randomized to finasteride, and 5-year data were available on 238 patients originally randomized to placebo. Results. After 6 years of treatment with finasteride 5 mg, the mean quasi-American Urological Association Symptom Score improved by 4.0 points, the median prostate volume decreased by 24%, and the mean maximal urinary flow rate increased by 2.9 mL/s (P

UR - http://www.scopus.com/inward/record.url?scp=0037381362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037381362&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(02)02548-7

DO - 10.1016/S0090-4295(02)02548-7

M3 - Article

C2 - 12670567

AN - SCOPUS:0037381362

VL - 61

SP - 791

EP - 796

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -